Epidemiology

British Journal of Cancer (2005) 93, 167–171. doi:10.1038/sj.bjc.6602674 www.bjcancer.com
Published online 21 June 2005

No association of breast cancer risk with integrin beta3 (ITGB3) Leu33Pro genotype

S E Bojesen1, A Tybjærg-Hansen2,3, C K Axelsson4 and B G Nordestgaard1,2

  1. 1Department of Clinical Biochemistry, Herlev University Hospital, Herlev Ringvej 75, Herlev DK-2730, Denmark
  2. 2The Copenhagen City Heart Study, Bispebjerg University Hospital, Bispebjerg Bakke 23, Copenhagen NV DK-2400, Denmark
  3. 3Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen Ø DK-2100, Denmark
  4. 4Department of Breast Surgery, Herlev University Hospital, Herlev Ringvej 75, Herlev DK-2730, Denmark

Correspondence: Professor BG Nordestgaard, E-mail: brno@herlevhosp.kbhamt.dk

Received 4 March 2005; Revised 4 May 2005; Accepted 23 May 2005; Published online 21 June 2005.

Top

Abstract

To pursue a borderline increased risk of breast cancer for carriers of two integrin beta3 (ITGB3) 33Pro alleles found in a recent prospective study, we conducted a case–control study of 1088 women with breast cancer and 4815 female controls. Leu33Pro heterozygotes, homozygotes and heterozygotes+homozygotes vs noncarriers had odds ratios for breast cancer of 1.0 (95% confidence interval: 0.8–1.1), 0.8 (0.5–1.2) and 1.0 (0.8–1.1), respectively. After stratification for conventional risk factors, odds ratio for breast cancer in heterozygotes, homozygotes and heterozygotes+homozygotes vs noncarriers were not increased above 1.0 in any of the 14 strata examined. This was also true after stratification for tumour histological subtype and cancer stage at the time of diagnosis.

Keywords:

integrins, breast cancer, genetic polymorphism, genetic epidemiology, case–control